These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25270570)

  • 1. The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.
    Li X; Wang C; Liang R; Sun F; Shi Y; Wang A; Liu W; Sun K; Li Y
    Pharm Res; 2015 Mar; 32(3):1017-27. PubMed ID: 25270570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport.
    Jin Y; Song Y; Zhu X; Zhou D; Chen C; Zhang Z; Huang Y
    Biomaterials; 2012 Feb; 33(5):1573-82. PubMed ID: 22093292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo.
    Nguyen HN; Wey SP; Juang JH; Sonaje K; Ho YC; Chuang EY; Hsu CW; Yen TC; Lin KJ; Sung HW
    Biomaterials; 2011 Apr; 32(10):2673-82. PubMed ID: 21256586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of CSK-DEX-PLGA Nanoparticles for the Oral Delivery of Exenatide to Improve Its Mucus Penetration and Intestinal Absorption.
    Song Y; Shi Y; Zhang L; Hu H; Zhang C; Yin M; Chu L; Yan X; Zhao M; Zhang X; Mu H; Sun K
    Mol Pharm; 2019 Feb; 16(2):518-532. PubMed ID: 30601014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
    Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS
    Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer.
    Chen G; Svirskis D; Lu W; Ying M; Huang Y; Wen J
    J Control Release; 2018 May; 277():142-153. PubMed ID: 29548985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
    Wang M; Zhang Y; Feng J; Gu T; Dong Q; Yang X; Sun Y; Wu Y; Chen Y; Kong W
    Int J Nanomedicine; 2013; 8():1141-54. PubMed ID: 23658482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
    Ahn S; Lee IH; Lee E; Kim H; Kim YC; Jon S
    J Control Release; 2013 Sep; 170(2):226-32. PubMed ID: 23747732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models.
    Eldor R; Kidron M; Greenberg-Shushlav Y; Arbit E
    J Diabetes Sci Technol; 2010 Nov; 4(6):1516-23. PubMed ID: 21129350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.
    Hu M; Zhang Y; Xiang N; Zhong Y; Gong T; Zhang ZR; Fu Y
    Pharm Res; 2016 Jun; 33(6):1318-26. PubMed ID: 26857900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of low molecular weight protamine to enhance oral absorption of exenatide.
    Zhang L; Shi Y; Song Y; Sun X; Zhang X; Sun K; Li Y
    Int J Pharm; 2018 Aug; 547(1-2):265-273. PubMed ID: 29800739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exendin-4 Loaded Nanoparticles with a Lipid Shell and Aqueous Core Containing Micelles for Enhanced Intestinal Absorption.
    Chen C; Zhu X; Dou Y; Xu J; Zhang J; Fan T; Du J; Liu K; Deng Y; Zhao L; Huang Y
    J Biomed Nanotechnol; 2015 May; 11(5):865-76. PubMed ID: 26349398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach.
    Soudry-Kochavi L; Naraykin N; Nassar T; Benita S
    J Control Release; 2015 Nov; 217():202-10. PubMed ID: 26381898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Goblet cell targeting nanoparticle containing drug-loaded micelle cores for oral delivery of insulin.
    Zhang P; Xu Y; Zhu X; Huang Y
    Int J Pharm; 2015 Dec; 496(2):993-1005. PubMed ID: 26541299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
    Chuang EY; Nguyen GT; Su FY; Lin KJ; Chen CT; Mi FL; Yen TC; Juang JH; Sung HW
    Biomaterials; 2013 Oct; 34(32):7994-8001. PubMed ID: 23891516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice.
    Shi Y; Sun X; Zhang L; Sun K; Li K; Li Y; Zhang Q
    Sci Rep; 2018 Jan; 8(1):726. PubMed ID: 29335533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide.
    Kim D; Jeon H; Ahn S; Choi WI; Kim S; Jon S
    J Control Release; 2017 Jun; 256():114-120. PubMed ID: 28457895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sol-gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus.
    Oh KS; Kim JY; Yoon BD; Lee M; Kim H; Kim M; Seo JH; Yuk SH
    Eur J Pharm Biopharm; 2014 Nov; 88(3):664-9. PubMed ID: 25152212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
    Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
    Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.